Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas by Duarte, Bruno Kosa Lino et al.
432                                                                                                                                              Rev Bras Hematol Hemoter. 2011;33(6):432-8
Brazilian experience using high dose sequential chemotherapy followed by
autologous hematopoietic stem cell transplantation for malignant lymphomas
1
Hematology and Hemotherapy Center,
Universidade Estadual de Campinas – UNICAMP,
Campinas, SP, Brazil
2
Data analysis and Statistics Center,
Hematology and Hemotherapy Center,
Universidade  Estadual de Campinas – UNICAMP,
Campinas,  SP, Brazil
3
Internal Medicine Department, Universidade
Federal do Rio de Janeiro – UFRJ,
Rio de Janeiro, RJ, Brazil
4
Internal Medicine Department, Escola
Estadual de Medicina de Marília, Marilia,
SP, Brazil
Bruno Kosa Lino Duarte1




José Francisco Comenalli Marques Jr1
Gislaine Borba Oliveira-Duarte1





Carmino Antonio de Souza1
Objective: To evaluate the use of high-dose sequential chemotherapy in a Brazilian population.
Methods: High-dose cyclophosphamide followed by autologous hematopoietic stem cell
transplantation is an effective and feasible therapy for refractory/relapsed lymphomas; this regimen
has never before been evaluated in a Brazilian population. All patients (106 with high-grade non-
Hodgkin lymphoma and 77 with Hodgkin's lymphoma) submitted to this treatment between 1998
and 2006 were analyzed. Chemotherapy consisted of the sequential administration of high-dose
cyclophosphamide (4 or 7 g/m2) and granulocyte-colony stimulating factor (300 µg/day), followed
by peripheral blood progenitor cell harvesting, administration of etoposide (2g/m2) and methotrexate
(8 g/m2 only for Hodgkin's lymphoma) and autologous hematopoietic stem cell transplantation.
Results: At diagnosis, non-Hodgkin lymphoma patients had a median age of 45 (range: 8-65) years
old, 78% had diffuse large B-cell lymphoma and 83% had stage III/IV disease. The Hodgkin's
lymphoma patients had a median age of 23 (range: 7-68) years old, 64.9% had the nodular sclerosis
subtype and 65% had stage III/IV disease. Nine Hodgkin's lymphoma patients (13%) and 10 (9%)
non-Hodgkin lymphoma patients had some kind of cardiac toxicity. The overall survival, disease-free
survival and progression-free survival in Hodgkin's lymphoma were 29%, 59% and 26%, respectively.
In non-Hodgkin lymphoma, these values were 40%, 49% and 31%, respectively. High-dose
cyclophosphamide-related mortality was 10% for Hodgkin's lymphoma and 5% for non-Hodgkin
lymphoma patients. High-dose cyclophosphamide dosing had no impact on toxicity or survival for
both groups.
Conclusions: Despite a greater prevalence of poor prognostic factors, our results are comparable to
the literature. The incidence of secondary neoplasias is noteworthy. Our study suggests that this
approach is efficient and feasible, regardless of toxicity-related mortality.
Keywords: Transplantation, autologous; Hodgkin disease/drug therapy; Lymphoma; Lymphoma,
non-Hodgkin; Antineoplastic Combined Chemotherapy Protocols/administration & dosage;
Cyclophosphamide/administration & dosage; Hematopoietic stem cell transplantation
Introduction
There have been many advances in the treatment of malignant lymphomas over the
last few decades. Even so, management of relapsed and resistant disease using conventional
chemotherapy is disappointing.
The use of state-of-the-art regimens, such as doxorubicin [Adriamycin], bleomycin,
vinblastine, dacarbazine (ABVD) and bleomycin, etoposide, adriamycin,
cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP), has improved the
outcome in Hodgkin's lymphoma (HL) and patients with good prognostic factors achieve
complete remission (CR) rates as high as 95%.(1,2) However, patients with advanced disease
and poor prognostic factors do not perform so well and present with either chemo-
resistant or relapsing disease. (3)
As for non-Hodgkin lymphomas (NHL), today, with Rituximab containing
cyclophosphamide, vincristine, doxorubicin, prednisolone (CHOP)-like regimens as standard
treatment, survival has improved significantly.(4,5) However, management of relapsed and
resistant disease with conventional salvage regimens is disappointing, with overall survival
(OS) rates lower than 10%.(1,6) The Parma Trial(7) showed the benefit of using high-dose
chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) as
salvage therapy giving response rates close to 90%. Nevertheless, more than 50% of these
patients relapsed and most died from progressive disease.(1)
In such a scenario, a dose intensified regimen, such as high-dose sequential
chemotherapy (HDS) followed by HSCT, represents an effective and feasible salvage therapy
for resistant and relapsed malignant lymphomas.(8,9)
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Despite proof of its efficacy for both HL(10,11) and
NHL,(12) there are few studies using this strategy in Brazil
and few groups worldwide evaluated the use of this therapy
with follow-up periods longer than 5 years. The use of this
strategy for HL has already been reported in patients from
this institution.(13) The objective of the current study was
to compare the experience of this strategy between 2 groups
of malignant lymphomas (HL and NHL). The aim was,
therefore, to evaluate the effectiveness and toxicity of HDS
used as a salvage therapy comparing these two groups of
malignant lymphomas, focusing on overall survival (OS),
disease-free survival (DFS) and progression-free survival
(PFS).
Methods
A retrospective analysis was performed of all refractory
HL patients (77) and high grade NHL patients (106) who
were submitted to HDS from May 1st 1998 to November 30th
2006 in two institutions: Hemocentro, University of
Campinas (UNICAMP) and Vera Cruz Hospital. Patients were
eligible for treatment if they had failed to achieve CR after
first-line treatment (non-responsive – NR) or presented with
relapsed disease, even if CR had been achieved before
mobilization. Patients were excluded if they have been
diagnosed with any psychiatric condition. All patients or
their legal representatives provided written informed
consent before receiving this regimen. Treatment
procedures were approved by the institutional review boards
of both participating institutions.
Treatment procedures and definitions
HDS consisted of the sequential administration of
high doses of cyclophosphamide (4 or 7 g/m2 depending
upon the patients' clinical features during treatment, in
particular age and heart function) and granulocyte colony
stimulating factor (G-CSF) 300 µg/day from day +1 after
high-dose cyclophosphamide (HDCY), followed by
peripheral blood progenitor cell (PBPC) harvesting, when the
white blood cell count (WBC) had increased to > 1.0 x 109/L
with the aim of collecting > 5 x 106 CD34+ cells/kg body
weight.
Patients with an insufficient number of CD34+ cells
underwent another collection after the administration of
etoposide. In some cases where peripheral cells could not
be harvestedfrom peripheral blood, harvesting was made
directly from the bone marrow. After PBPC harvesting,
methotrexate (8 g/m2) plus vincristine (1.4 mg/m2) – only in
patients with HL – and etoposide (2 g/m2) were administered.
Different regimens HDS were then administered including
carmustine, etoposide, cytarabine and melphalan (BEAM),
cyclophosphamide, carmustine, and etoposide (CBV) and
mitoxantrone and melphalan (Mito/Melph). Subsequently,
autologous HSCT was performed.
Disease status was assessed by abdominal ultrasound
and computed tomography (CT), depending on the sites of
disease. Positron Emission Tomography/CT was not
available for response assessment. These assessments,
when possible, were performed before HDCY, before and
after autologous HSCT and throughout the long-term
follow-up (every 3 months in the first year, every 6 months
in the second year and annually thereafter). CR was defined
as the absence of clinical, laboratory and imaging findings
confirming absence of disease persisting for at least 3
months. Partial remission (PR) was defined as a tumor mass
reduction > 50% after treatment. Non-responsive (NR) disease
was defined when a reduction in tumor mass of < 50% was
observed and disease progression was defined as an
increase in tumor mass after treatment, or a new tumor mass
or central nervous system infiltration during treatment.
Relapsed disease (RD) was defined as the re-appearance of
disease identified by clinical, laboratory or imaging findings
after CR had been achieved.
Data collection and statistical analysis
Analysis was based on data as of May 2010.
Dichotomous variables were compared using the Fisher's
exact or Chi-square tests, as appropriate, whereas continuous
variables were compared using the Mann-Whitney test.
Actuarial curves of OS, DFS and PFS were analyzed using
the Kaplan-Meier method, and compared by the log-rank test.
Multivariate predictors of outcome (OS, DFS and PFS) were
assessed by Cox regression analysis, using the forward
stepwise Wald test. Statistical analysis was performed using




Seventy-seven HL patients and 106 NHL patients were
enrolled in the study. HL histological types, according to
World Health Organization (WHO) criteria(14) were: nodular
sclerosis in 51 patients (66.2%); mixed cellularity in 20 (26%);
lymphocyte depleted in five (6.5%) and lymphocyte
predominant in one (1.3%). The NHL histopathological
classifications according to WHO criteria(14) were: diffuse
large B-cell lymphoma (DLBCL) in 83 patients (78.3%), T and
anaplastic lymphoma in 13 patients (12.3%) and mantle cell
lymphoma in 10 patients (9.4%). Table 1 shows the
characteristics of these patients.
Before HDCY, 41 HL patients (53.2%) and 25 NHL
patients (24%) received radiation therapy, either as a
consolidation therapy, as a treatment for relapsed disease, or
as treatment for oncologic emergencies. One HL and six NHL
patients were in CR after conventional treatment for their
first relapse before being referred to the institution.
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Mobilization, peripheral blood progenitor cell
harvesting and toxicity
Cyclophosphamide was administered after a median
of 1.5 years from diagnosis for HL patients and after 10
months for NHL patients. Thirty HL patients (39%) and 64
NHL patients (60.4%) received a dose of 4 g/m2 due to
advanced age (> 65 years) or borderline heart function. There
were no differences in gender, histopathological subtype,
LDH values, bone marrow involvement, bulky disease,
stage, or number of previous chemotherapy lines between
the two 4 and 7 g/m2 groups for both HL and NHL.
The median time between the completion of HDCY
and leukapheresis was 13 days for both HL (range: 8-27)
and NHL (range: 3-83) groups, with a median of three
sessions (range: 1-8) for HL and two sessions (range: 1-7)
for NHL and a median number of harvested CD34+ cells of
5.98 x 106 (range: 0.23-45.01 x 106) cells/kg body weight for
HL and 6.74 x 106 (range: 1.29-44.01 x 106) cells/kg body
weight for NHL patients.
Twenty-two HL patients (27.3%) died after HDCY, but
only eight (10.4%) died from treatment-related toxicity (two
from sepsis, one from liver failure, one from tumor lysis
syndrome, two from refractory congestive heart failure and
two due to high-dose methotrexate-toxicity). Ten died from
DP and three died from sepsis while in DP. Finally, one
patient did no collect enough cells, evolved with
myelodysplastic syndrome (MDS) and died from sepsis while
in CR. In addition to these 22 patients, two more were not
submitted to HSCT: one lost follow-up and one was awaiting
HSCT at closure of this analysis.
Nineteen NHL patients (18%) died after HDCY. Six
patients (5.7%) died from HDCY-related toxicity (one with
tumor lysis syndrome, four from sepsis and one from
invasive pulmonary aspergillosis), nine from DP, three from
sepsis while in DP and one from sepsis not related to therapy
in PR. In addition, seven other patients did not undergo
autologous HSCT: five did not consent, one was diagnosed
with esophageal varices and became ineligible for the
procedure, and one lost follow-up giving a total of 26
patients (24.5%) who were not submitted to autologous
HSCT.
Data on toxicity were recorded for 71 HL patients and
102 NHL patients. Sixty-six HL patients (93%) and 94 (88.6%)
NHL patients had WHO grade IV toxicity for white blood
cell counts (neutropenia). Forty HL patients (56%) and 47
NHL patients (44%) experienced some kind of
gastrointestinal toxicity. Additionally, nine HL patients
(13%) presented cardiac toxicity of some type with two dying
due to myocarditis. Similarly, ten NHL patients (9.4%) had
some kind of cardiac toxicity with one dying from severe
congestive heart failure.
Seven HL patients (9.7%) and four NHL patients (3.8%)
developed acute renal failure not related to sepsis.
Hematopoietic stem cell transplantation
results
Autologous HSCT was performed in 53 HL patients
(68.8%) and 80 NHL patients (75.5%), with median times of
four months (range: 2-13) and two months (range: 1-15) after
HDCY, respectively. Two patients, one with HL and another
with NHL, who achieved CR after HDCY, decided to undergo
HSCT only 56 and 57 months after HDCY, respectively.
BEAM was the most frequently used conditioning regime,
administered to 43 HL patients (81%) and 70 NHL patients
(87%). The median times for granulocyte (> 0.5 x 109/L) and
platelet (> 20 x 109/L) engraftment were 11 (range: 9-27) and
17 days (range: 6-88) for HL patients and 11 (range: 6-29)
and 16 (range: 5-70) days for NHL patients, respectively.
Mortality related to autografts occurred in six HL patients
(11%): three due to pulmonary hemorrhage, one due to
tumor lysis syndrome and two due to fungemia. As for NHL
patients, HSCT-related mortality occurred in ten (12%)
patients: one from acute heart failure, one from fusariosis,
Duarte BK, Miranda EC, Nucci M, Vigorito AC, Penteado FJ, Marques Jr JF, et al
 Rev Bras Hematol Hemoter. 2011;33(6):432-8                                                                                                                                             435
one from herpetic encephalitis, one from typhlitis, one from
cytomegalovirus pneumonitis, one from pulmonary
hemorrhage and four from sepsis. Two patients died from
engraftment syndrome, one in the HL group and one in the
NHL group. OS for transplanted patients was 46% for
patients with HL and 49% for patients with NHL.
Long-term Outcome
Distributions of status in different treatment stages can
be seen in Table 2. A total of 27 patients with HL and 48 with
NHL are alive in a median of 66 (range: 3-128) and 68 (range:
1-115) months after HDCY, respectively.
OS, DFS and PFS data for both HL and NHL are shown
in Figure 1. Median durations of OS, DFS, and PFS for HL
were 18 (range: 1-128), 45 (range: 2-125) and 13 (range:
1-128) months, respectively and for NHL patients they
were 29 (range: 1-125), 36 (range: 2-118.2) and 17 months
(range: 1-115), respectively.
The survival of patients initially in DP (57/77– 74% for
HL patients and 62/106 – 58%) were analyzed according to
their disease status before HDCY. Patients who achieved
CR after HDCY (24/57 – 42% for HL patients and 38/62 –
61% for NHL patients) had significantly better OS and PFS
(36% and 33% respectively, for HL and 44 and 22%,
respectively, for NHL) than patients who remained in DP
(10% [p-value = 0.002] and 17% [p-value = 0.001]
respectively, for HL patients and 0% [p-value < 0.001] and
0% [p-value = 0.003], respectively, for NHL patients – Figure
2). The survival of patients according to HDCY dose was
also analyzed but there was no statistical significant difference
between the 4 g/m2 and 7 g/m2 groups.
For NHL patients, those who presented without B
symptoms had better OS and PFS (60% and 39%, respectively)
than patients with B symptoms (26% and 26%, respectively;
p-value = 0.002 and p-value = 0.042, respectively). Survival
data based on age, stage, histopathological and laboratory
findings at diagnosis were also analyzed; there was no
association between survival and any of these variables.
Of the variables included in the univariate analysis of
HL patients, DP before (hazard ratio [HR]: 2.34; 95%
confidence interval [95% CI]: 1.13-4.84; p-value < 0.02) and
Figure 1 – Overall (OS), disease-free (DFS) and progression-free survival (DFS) for all 77 Hodgkin's lymphoma and 106 non-Hodgkin lymphoma
patients by the Kaplan-Meier method
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after HDCY (HR: 3.46; 95% CI: 1.7-6.6; p-value < 0.0001) were
associated with poorer OS, as was high serum LDH level
(HR: 2.37; 95% CI: 1.22-4.60; p-value < 0.01) both as
continuous or categorical variables. In the univariate
analysis of NHL patients, only DP before (HR: 2.66; 95% CI:
1.48-4.78; p-value < 0.001) and after HDCY (HR: 5.91; 95%
CI: 3.25-10.73; p-value < 0.001) were associated with poorer
OS. By multivariate analysis, two variables remained
significant for HL patients: serum LDH (as a categorical
variable - HR: 2.41; 95% CI: 1.04-5.59; p-value = 0.04) and
DP after HDCY (HR: 3.97; 95% CI: 1.73-9.10; p-value = 0.001).
As for NHL patients, two variables related to disease at the
time of diagnosis maintained their prognostic value for
overall survival by multivariate analysis. These findings
are summarized in Table 3.
Discussion
This study offers the first analysis of a large Brazilian
cohort submitted to HDS chemotherapy for high-risk
lymphoma. The analysis of a Brazilian cohort has several
implications because the frequency of some important poor
prognostic factors, such as B symptoms and bulky disease,
are higher in our patients compared to cohorts from the
Northern Hemisphere.(15-17) In an Italian study(18) evaluating
HDS in 102 patients with refractory or recurrent HL, 42%
had B symptoms and 29% had bulky disease. In another
study(19) evaluating the use of HDT and autologous HSCT
in 494 Spanish patients with refractory or recurrent HL,
40.5% had B symptoms and 33% had bulky disease. These
numbers contrast with the 71% of patients with B symptoms
and the 40% of patients with bulky disease seen in our
patients with HL. The same is true with NHL patients. The
higher prevalence of such variables in our population
indicates that they are probably expected to have poorer
results when compared to other populations in developed
countries, despite differences in the therapeutic strategies
employed.
Another possible factor contributing to a worse
outcome in our patients is a higher prevalence of Epstein-
Barr virus (EBV)-associated HL, although we did not
investigate this information. Despite the controversy
surrounding the possible influence of EBV in the outcome of
HL, some studies suggest that the OS is worse in adult
patients with EBV-associated HL.(20) While the prevalence of
Figure 2 – Overall survival according to disease status after high-dose cyclophosphamide [complete remission (CR) and partial remission (PR) vs.
disease progression (DP)] in patients initially in DP by the Kaplan Meier method with Log Rank test
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EBV in developed countries is around 30%,(20) one study
performed at the institution of the current study showed a
prevalence of 64%.(16) The aforementioned differences may
be due to low socioeconomic status(16) as this is a
governmental institution which provides care to low income
patients, and not due to ethnical differences between our
population and those from developed countries.(16)
The higher prevalence of poor prognostic factors in
this population reflects in poorer OS and PFS of HL patients
(27 and 25%) compared to other studies in which the OS
and PFS ranged from 50 to 65%.(18, 21) However, this was not
observed for NHL patients, with an OS of 41% and a PFS of
31%, similar to those reported in other studies (40 to
45%).(12,21,22) Although a higher prevalence of high-risk
patients may explain the worse OS observed in the HL
patients of this study, it should also have negatively
impacted survival of NHL patients. This finding in a
population of similar sociodemographic conditions with
advanced disease treated under the same protocol and
within the same institution highlights the different biology
of both diseases and points to a need of different salvage
strategies for each.
These data show the necessity of a review of HDCY
use in HL, which is usually a more benign disease, as patients
may benefit from less intensive regimens; a recent study
comparing HDCY with BEAM as salvage therapies, showed
no benefit of the dose intensified therapy (HDCY) on PFS
and OS.(23)
A lack of benefit of using a higher dose regimen for
both HL and NHL was not expected. The use of a regimen at
two different doses (4 g/m2 and 7 g/m2) was based on findings
of the Italian group.(22) This was developed based on the
Norton-Simon hypothesis,(24) which states that an ideal
treatment should seek the highest possible dosing, over the
minimum period of time, with an acceptable toxicity. By
showing no extra benefit of the higher dose regimen, either in
OS or in response rates, our study suggests that its benefit
was exceeded by its toxicity, resulting in the similar survival
rate to the lower dose regimen.
Even though the 7g/m2 regimen did not improve
survival, the role of a high-dose debulking regimen is
highlighted by the observation that patients previously in
DP, who responded to HDCY and achieved a CR, had a better
overall survival. This not only shows the ability of HDCY to
overcome primary chemoresistance in a significant proportion
of refractory patients, but also its importance in assessing
chemosensitivity of lymphoma, since there was no benefit in
submitting patients to autologous HSCT when they did not
respond to HDCY, with no additional benefit of autologous
HSCT in patients in DP.
Nevertheless, this high-dose debulking regimen
imposed a high toxicity burden (cardiological, renal and
gastrointestinal), with HDCY-related mortality of 5.7% for
NHL and 10.4% for HL, which is slightly worse than the 5%
rate observed elsewhere,(22) but still acceptable. Moreover, a
mortality rate of 10% for autologous transplantation is
noteworthy, further corroborating the toxicity burden
associated with this therapy.
Another point that should be noted is the incidence of
secondary hematological malignancy, especially in HL
patients. Death due to secondary cancers represents the most
common cause of mortality among long-term survivors of
HL.(25) The incidence of secondary hematological
malignancies in our study was 5.2%. This rate appears to be
similar to rates observed in other studies,(26,27) and although
credited to the cytotoxic effects of alkylating agents, the role
of cytogenetic instability related to the disease and
autologous HSCT has yet to be determined, especially when
we consider the significantly lower incidence of this
complication in patients with NHL in our study (0.9%), treated
under the same regimen.
Conclusions
This study has some limitations typical of retrospective
studies. However, it can be concluded that despite the
significant number of toxicity-related deaths, the data of this
study suggest that this regimen is feasible, mainly for
chemosensitive patients. The development of secondary
neoplasia is a special concern in this setting, particularly for
HL patients.
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